Abstract: The present invention relates to a continuous process for preparing a polyisocyanate, in which a polyamine and phosgene are first converted predominantly to carbamoyl chloride and amine hydrochloride and only in minor proportions to polyisocyanate, and a portion of the carbamoyl chloride- and amine hydrochloride-containing reaction mixture thus obtained is recycled into the reaction with phosgene, wherein polyamine, phosgene and the carbamoyl chloride- and amine hydrochloride-containing reaction mixture are mixed intimately in a mixing unit. The portion of the carbamoyl chloride- and amine hydrochloride-containing reaction mixture which is not recycled into the phosgenation is worked up to give the polyisocyanate.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: The invention relates to a method for producing isocyanates by reacting the corresponding primary amines with phosgene in the gas phase, wherein the phosgene is injected into the gaseous amine flow in the interior of the flow tube via an outer ring channel and through several radial channels in an angle of ?90° relative to the flow direction of the gaseous amine flow, wherein a static mixer of the KENICS type is provided coaxially in the interior of the flow tube.

Abstract: The invention relates to a method for producing 1,5-pentanediisocyanate (PDI) by reacting 1,5-pentanediamine (PDA) with phosgene in the gas phase.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterised in that it exhibits a low effective flow rate of less than about 5 liters per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis.

Abstract: The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. Some embodiments relate to dosage forms. Dosage forms can include an aqueous pharmaceutical composition containing (i) from about 2% to about 6% by weight of cromolyn sodium, and (ii) an osmolarity adjusting agent consisting of (A) between about 0.1% to about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (B) optionally salts of EDTA; and an inhalation device that forms an aerosol of said pharmaceutical composition, said aerosol exhibiting a respirable fraction of said pharmaceutical composition (<5 ?m) as measured by USP <1601> of at least about 60%, are provided.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: Methods for the treatment of lung diseases with mast cell stabilizers are provided.

Abstract: The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: Methods for the treatment of lung diseases with mast cell stabilizers are provided.

Abstract: The present invention provides dry powder formulations for inhalation having improved moisture resistance such that the powders maintain a high fine particle dosage or fine particle fraction following storage under relatively extreme temperature and humidity conditions.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: Liquid aqueous pharmaceutical solutions, containing a mast cell stabilizing active agent for application to the upper and lower respiratory tract or in the eye are provided. The solutions comprise both a non-ionic and an ionic tonicity-adjusting excipient. They are particularly useful for the aerosol treatment of respiratory diseases such as asthma. Furthermore, methods for nebulization of these solutions and methods of packaging the solutions are provided.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Abstract: The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.

Abstract: Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.